Loading…
Citius Pharmaceuticals, Inc. is projected to rise to $0.65 by 2027, a +9% move from its current price of $0.596. CTXR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.5648 | $0.5965 | $0.6299 | +0.08% |
| Aug 6 | $0.5527 | $0.5969 | $0.6448 | +0.16% |
| Aug 7 | $0.5436 | $0.5974 | $0.6565 | +0.24% |
| Aug 8 | $0.5361 | $0.5979 | $0.6667 | +0.31% |
| Aug 9 | $0.5297 | $0.5983 | $0.6759 | +0.39% |
| Aug 10 | $0.524 | $0.5988 | $0.6843 | +0.47% |
| Aug 11 | $0.5188 | $0.5993 | $0.6922 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5188 | $0.5993 | $0.6922 | +0.55% |
| Week 2 | $0.4914 | $0.6026 | $0.7389 | +1.10% |
| Week 3 | $0.472 | $0.6059 | $0.7778 | +1.66% |
| Week 4 | $0.4566 | $0.6092 | $0.8129 | +2.22% |
| Week 5 | $0.4437 | $0.6125 | $0.8456 | +2.78% |
| Week 6 | $0.4326 | $0.6159 | $0.8768 | +3.34% |
| Week 7 | $0.4229 | $0.6193 | $0.907 | +3.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR is the ticker for Citius Pharmaceuticals, Inc., a healthcare company. The current price is $0.57 and the market cap is $15.65M, with a rank of 4948. These figures place CTXR among small-cap listings within the broader market.
A major floor 31.2% below — a decisive break under it would weaken the trend.
The nearest floor, 19.3% below — buyers have tended to step in here.
The nearest ceiling, 6.0% above — a clean break opens room to run.
A major ceiling 56.5% above — clearing it would confirm fresh momentum.
Key CTXR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTXR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5572 | Buy | $0.5676 | Buy |
| MA 10 | $0.5426 | Buy | $0.5541 | Buy |
| MA 20 | $0.5464 | Buy | $0.5518 | Buy |
| MA 50 | $0.5735 | Buy | $0.5838 | Buy |
| MA 100 | $0.6703 | Sell | $0.6646 | Sell |
| MA 200 | $0.8574 | Sell | $1.03 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.78 | Neutral |
| Stoch RSI (14) | 65.29 | Neutral |
| CCI (20) | 50.98 | Neutral |
| Williams %R (14) | -41.06 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 7.34 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 58.94 | Neutral |
| TRIX (15) | -0.32 | Sell |
| Awesome (5,34) | 0.00 | Buy |
| Ultimate (7,14,28) | 51.96 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 0.59 | Buy |
| ADX (14) | 12.70 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 50. The near-term setup shows SMA50 at $0.5735 and SMA200 at $0.8574, with support at $0.481 and resistance at $0.632. The 30-day price range runs from $0.398 to $0.8164, and annualized volatility sits at 100.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.481 | $0.596 | $0.8246 | 0% | Neutral | |
| $0.4737 | $0.65 | $0.964 | +9% | Neutral | |
| $0.3459 | $0.5049 | $0.799 | -15% | Bearish | |
| $0.334 | $0.5137 | $0.8541 | -14% | Neutral | |
| $0.3232 | $0.5212 | $0.9025 | -13% | Neutral | |
| $0.3027 | $0.5103 | $0.9149 | -14% | Neutral | |
| $0.3928 | $0.6908 | $1.28 | +16% | Neutral | |
| $0.4078 | $0.747 | $1.42 | +25% | Bullish | |
| $0.3849 | $0.7335 | $1.43 | +23% | Bullish | |
| $0.3481 | $0.6894 | $1.38 | +16% | Neutral | |
| $0.4461 | $0.9914 | $2.17 | +66% | Bullish | |
| $0.5771 | $1.28 | $2.95 | +115% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.481 | $0.596 | $0.7209 | +0.00% |
| September 2026 | $0.5086 | $0.6182 | $0.784 | +3.72% |
| October 2026 | $0.5193 | $0.6401 | $0.8283 | +3.54% |
| November 2026 | $0.4954 | $0.6176 | $0.8123 | -3.51% |
| December 2026 | $0.4906 | $0.618 | $0.8246 | +0.07% |
Click any year to see its month-by-month CTXR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Citius Pharmaceuticals, Inc.'s 2026 outlook centres on $0.596, within a $0.481 to $0.8246 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CTXR could reach as high as $0.964, with a base case around $0.65 and support toward $0.4737 — roughly +9% from $0.596. A consolidation phase looks the most probable path here.
Expect CTXR to range from $0.3459 to $0.799 through 2028. The $0.5049 average target implies a -15% move from current prices. That is -22% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The CTXR price prediction for 2029 points to an average of $0.5137 (low $0.334, high $0.8541) — a potential decline of -14% on today's $0.596. A consolidation phase looks the most probable path here.
In 2030, CTXR is projected to trade between $0.3232 and $0.9025, averaging $0.5212 — a potential decline of -13% from today's $0.596. That is up +1% on the projected 2029 average. Price action looks broadly range-bound.
Citius Pharmaceuticals, Inc.'s 2031 outlook centres on $0.5103, within a $0.3027 to $0.9149 range. That is -2% versus the projected 2030 average. That marks a -14% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, CTXR could reach as high as $1.28, with a base case around $0.6908 and support toward $0.3928 — roughly +16% from $0.596. Price action looks broadly range-bound.
Expect CTXR to range from $0.4078 to $1.42 through 2033. The $0.747 average target implies a +25% move from current prices. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CTXR price prediction for 2034 points to an average of $0.7335 (low $0.3849, high $1.43) — a potential gain of +23% on today's $0.596. Momentum favours further upside here.
In 2035, CTXR is projected to trade between $0.3481 and $1.38, averaging $0.6894 — a potential gain of +16% from today's $0.596. That is -6% versus the projected 2034 average. A consolidation phase looks the most probable path here.
Citius Pharmaceuticals, Inc.'s 2040 outlook centres on $0.9914, within a $0.4461 to $2.17 range. That is up +44% on the projected 2035 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2050, CTXR could reach as high as $2.95, with a base case around $1.28 and support toward $0.5771 — roughly +115% from $0.596. Buyers look set to stay in control over this stretch.
Investing $1,000 in CTXR today (≈ 1,677.852349 CTXR) could be worth
$2,151.69
+$1,151.69 (+115%) by 2050 · US Dollar
Based on the average projected CTXR price of $1.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTXRwould be worth at today's price.
$1,000 invested in CTXR on Jul 31, 2025 (≈ 729.927005 CTXR) would be worth
$435.04
-$564.96 (-56.5%) today · 0.44× · US Dollar
Based on a CTXR entry price of $1.37 vs. today's $0.596.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.52 | $1,146.15 | +14.6% |
| 1 month ago | $0.609 | $978.65 | -2.1% |
| 3 months ago | $0.7 | $851.43 | -14.9% |
| 6 months ago | $0.76 | $784.21 | -21.6% |
| 1 year ago | $1.37 | $435.04 | -56.5% |
| All time (5.0y) ago | $47.5 | $12.55 | -98.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTXR forecast.
Our base-case forecast reaches $1.20 around 2050.
Implied market cap at $1.20: $32.94M
The multi-year forecast shows a mixed trajectory before turning more constructive later in the horizon. In 2028 the outlook is BEARISH with an average price of $0.4816 and a negative ROI of -15.5, while 2027 remains NEUTRAL with an average of $0.6217. From 2032 onward, the path improves: 2032 avg $0.6622 (ROI 16.2), 2033 avg $0.7154 (ROI 25.5), and 2034 avg $0.7001 (ROI 22.8), followed by gradual gains through 2035 (avg $0.6605, ROI 15.9).
The horizon shifts higher in 2040 with an avg of $0.947 and a max of $2.08 (ROI 66.1) and remains bullish into 2050, with an avg of $1.23 and a max of $2.83 (ROI 115.8). These figures illustrate a late-long-run upside, tempered by earlier periods of weakness; they are estimates and not guarantees.
Tap a question to reveal the answer.
2030: min $0.3094, avg $0.4991, max $0.8642; ROI -12.4; sentiment NEUTRAL.
Forecasts show mixed timing: negative ROI in 2028 (-15.5), 2029 (-13.6), 2030 (-12.4), and 2031 (-14.6) with NEUTRAL sentiment, but potential upside from 2032 onward (2032 ROI 16.2; 2033 25.5; 2040 66.1; 2050 115.8). This is not a guarantee of returns and reflects modeled estimates.
Yes in several forecast years: 2032 max $1.22, 2033 max $1.36, 2034 max $1.36, with higher upside in later years (2040 max $2.08; 2050 max $2.83).
2040 min $0.4261, avg $0.947, max $2.08; ROI 66.1; sentiment BULLISH.
Current price is $0.57; market cap is $15.65M.
Citius Pharmaceuticals, Inc. Community Discussion
0Share your Citius Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.